EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Uveal Melanoma: Biology, Prognostication, and Emerging Therapies to Outsmart an Immune-Cold Melanoma

Danielle Brazel iD, Elizabeth Buchbinder iD

Cancers · 29.01.2026 · 18 (3) · 432

DOI: 10.3390/cancers18030432 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.01.2026. Verfasst von Danielle Brazel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Scripps Health, La Jolla, CA 92037, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uveal melanoma (UM) is a rare but highly aggressive malignancy arising from melanocytes of the uveal tract. Despite high local control rates for primary disease, half of patients ultimately develop metastatic disease with historically dismal outcomes. Unlike cutaneous melanoma, UM is characterized by a low tumor mutational burden, distinct driver mutations, and an immunosuppressive tumor microenvironment which together limit the efficacy of immune checkpoint inhibitors. Over the past decade, major advancements in molecular classification, prognostication, and therapeutic development have reshaped the clinical landscape for some patients with UM. This review synthesizes the current understanding of UM epidemiology, characteristics, prognostic biomarkers, immune biology, and contemporary management for both localized and metastatic disease. While survival gains remain modest, the rapid expansion of biologically informed and immune-based strategies offers cautious optimism for improving outcomes in this historically treatment-refractory disease.

Schlagwörter

Stichwörter der Autor:innen

BAP1adoptive cell therapyimmunotherapyliver-directed therapymonosomy 3targeted therapytebentafusptumor microenvironmentuveal melanoma

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Scripps Health, La Jolla, CA 92037, USA.
  • Department of Medical Oncology, Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA 02114, USA.

ORCID-Profile: Danielle Brazel, Elizabeth Buchbinder

Zitieren

APA

Brazel, D., & Buchbinder, E. (2026). Uveal Melanoma: Biology, Prognostication, and Emerging Therapies to Outsmart an Immune-Cold Melanoma. Cancers, 18(3), 432. https://doi.org/10.3390/cancers18030432

Vancouver

Brazel D, Buchbinder E. Uveal Melanoma: Biology, Prognostication, and Emerging Therapies to Outsmart an Immune-Cold Melanoma. Cancers. 2026;18(3):432. doi:10.3390/cancers18030432

BibTeX
@article{Brazel2026,
  author = {Brazel, Danielle and Buchbinder, Elizabeth},
  title = {Uveal Melanoma: Biology, Prognostication, and Emerging Therapies to Outsmart an Immune-Cold Melanoma},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {432},
  doi = {10.3390/cancers18030432}
}
Kostenlos starten →